We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




IFN-γ Signature Distinguishes Pediatric Hemophagocytic Lymphohistiocytosis from Sepsis and SIRS

By LabMedica International staff writers
Posted on 04 Oct 2021
Hemophagocytic lymphohistiocytosis (HLH), severe sepsis, and persistent systemic inflammatory response syndrome are all conditions defined by excessive immune activation that may progress rapidly and are associated high risk of death without early introduction of appropriate therapy.

Hemophagocytic lymphohistiocytosis (HLH) is a syndrome characterized by pathologic immune activation in which prompt recognition and initiation of immune suppression is essential for survival. More...
Children with HLH have many overlapping clinical features with critically ill children with sepsis and systemic inflammatory response syndrome (SIRS) in whom alternative therapies are indicated.

A large team of Pediatric Hematologists at the Baylor College of Medicine (Houston, TX, USA) collected sand processed blood samples of 40 patients with HLH and 47 pediatric patients with severe sepsis or SIRS. Plasma protein levels of 135 analytes representing cytokines, chemokines, and growth factors were determined using Milliplex MAP antibody panels (Millipore, Burlington, MA, USA) for the MagPix instrument (Luminex Corporation, Austin, TX, USA). Ferritin and interleukin-18 (IL-18) were analyzed in independent MagPix assays.

Peripheral blood mononuclear cells were sorted for CD3, CD4, CD8), and CD68 using the BD Aria Fusion (BD Bioscience, Franklin Lakes, NJ, USA). cDNA was prepared from CD3+8+ and CD3−68+ populations with the Nugen Ovation Pico WTA System V2 (Nugen, Redwood City, CA, USA). Gene expression data were generated using Affymetrix GeneChip Human Transcriptome Array 2.0 (Affymetrix, Santa Clara, CA, USA).

The scientists reported that 15 of 135 analytes were significantly different in HLH plasma compared with SIRS/sepsis, including increased interferon-γ (IFN-γ)–regulated chemokines CXCL9, CXCL10, and CXCL11. Furthermore, a 2-analyte plasma protein classifier including CXCL9 and interleukin-6 was able to differentiate HLH from SIRS/sepsis. Gene expression in CD8+ T cells and activated monocytes from blood were also enriched for IFN-γ pathway signatures in peripheral blood cells from patients with HLH compared with SIRS/sepsis.

Of the 40 pediatric HLH subjects, nine had biallelic gene mutations known to cause HLH (or monoallelic X-linked SH2D1A), four had single allele variants associated with HLH, and 11 had variants of uncertain significance in genes associated with immune functions potentially associated with immune dysregulation and HLH susceptibility.

The authors concluded that in their study they had identified differential expression of inflammatory proteins as a diagnostic strategy to identify critically ill children with HLH. Comprehensive unbiased analysis of inflammatory plasma proteins and global gene expression demonstrated that IFN-γ signaling is uniquely elevated in HLH. The study was published on September 10, 2021 in the journal Blood Advances.

Related Links:
Baylor College of Medicine
Millipore
Luminex Corporation
BD Bioscience
Nugen
Affymetrix



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Manual Pipetting Aid
Pipette Controllers macro
New
Slide Scanner System
NanoZoomer S540MD
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.